Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416

NCT01932970 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01932970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01932970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
August 12, 2013
Completion date
February 14, 2017
Enrollment
158 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

hyperparathyroidism, secondary